Figure 4.
Anxiety and motor activity assessment in nestin/hRAMP1 mice. A, TMT induced freezing behavior in untreated nestin/hRAMP1 mice (n = 8) compared with control littermates (n = 9). B, TMT induced freezing behavior in nestin/hRAMP1 mice after intracerebroventricular vehicle (n = 7) and CGRP (n = 9), compared with control littermates after intracerebroventricular vehicle (n = 6) and CGRP (n = 9). Left panel shows freezing behavior over time; right panel shows total freezing behavior in 10 min. Two-way ANOVA revealed no significant effects over 10 min; however, in the first 4 min, there was a significant main effect of CGRP (F(1,27) = 6.36, p = 0.02), no main effect of genotype (F <1), and no CGRP × genotype interaction (F <1). C, Percentage of time spent in the center of open field by untreated nestin/hRAMP1 mice and control littermates and after intracerebroventricular vehicle or CGRP (n = 10–11 per group). One-way ANOVA revealed no significant differences between the groups (F(5,58) = 1.61, p = 0.339). D, Motility in open field by nestin/hRAMP1 and control littermates untreated and after intracerebroventricular vehicle or CGRP (n = 10–11 per group). Two-way ANOVA revealed significant main effects of genotype (F(1,58) = 10.5, p = 0.002) and treatment (no injection vs vehicle vs CGRP; F(2,58) = 39.3, p < 0.001) and no genotype by treatment interaction (F <1). Post hoc pairwise comparisons (least significant difference) revealed no difference in motor activity in untreated nestin/hRAMP1 versus control littermates. Significant post hoc comparisons (*p < 0.05) are indicated. Error bars indicate SEM.